Beam Therapeutics

ISIN US07373V1052

 | 

WKN A2PY7P

Market cap (in EUR)
2 580 M
Country
États-Unis
Sector
Santé
Dividend yield
0,00%
 

Overview

Description

Beam Therapeutics, Inc. est une société de biotechnologie qui se consacre à la mise en place d'une plateforme intégrée pour les médicaments génétiques de précision. Son portefeuille de produits comprend BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301 et BEAM-201. La société a été fondée par David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli et J. Keith Joung le 25 janvier 2017 et son siège social se trouve à Cambridge, MA.
Show more Show less
Santé Produits biopharmaceutiques Autres produits biopharmaceutiques États-Unis

Financials

Key metrics

Market capitalisation, EUR 2 580 M
EPS, EUR -0,90
P/B ratio 2,4
P/E ratio -
Dividend yield 0,00%

Income statement (2025)

Revenue, EUR 124 M
Net income, EUR -71 M
Profit margin -57,24%

What ETF is Beam Therapeutics in?

There are 4 ETFs which contain Beam Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Beam Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.19%
Equity
United States
Health Care
Biotech
45
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
506
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.00%
Equity
North America
Social/Environmental
25
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.03%
Equity
United States
Small Cap
201
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.